



Yttrium 90 Ibritumomab Tiuxetan

Revised: November 15, 2023.

CASRN: 1460293-15-5

Drug Levels and Effects

Summary of Use during Lactation

Information in this record refers to the use of yttrium 90 ibritumomab tiuxetan as a therapeutic agent. No information is available on the use of yttrium 90 ibritumomab tiuxetan during breastfeeding. Because of the long half-life of yttrium 90, the manufacturer and expert opinion recommend not administering the drug in women who wish to continue breastfeeding.[1] If the drug is administered to a nursing mother, breastfeeding should be discontinued. No restrictions on holding the infant after administration of the drug are necessary.[2]

Drug Levels

Yttrium-90 decays by emission of beta particles, with a physical half-life of 64.1 hours and a decay energy of 2.28 MeV.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. *Semin Nucl Med* 2010;40:122-35. PubMed PMID: 20113680.
2. Gulec SA, Siegel JA. Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres. *J Nucl Med* 2007;48:2080-6. PubMed PMID: 18006608.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Substance Identification

Substance Name

Yttrium 90 Ibritumomab Tiuxetan

CAS Registry Number

1460293-15-5

Drug Class

Breast Feeding

Lactation

Milk, Human

Radiopharmaceuticals

Yttrium Radioisotopes